Welcome to our dedicated page for Entasis Therapeutics Holdings news (Ticker: ETTX), a resource for investors and traders seeking the latest updates and insights on Entasis Therapeutics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entasis Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entasis Therapeutics Holdings's position in the market.
Entasis Therapeutics Holdings (NASDAQ:ETTX) will host a virtual webinar on August 24, 2021, featuring experts David van Duin and Michael J. Rybak discussing the impact of Acinetobacter infections. The company will also provide updates on its antibiotic, sulbactam-durlobactam (SUL-DUR), which has completed enrollment in a Phase 3 trial targeting Acinetobacter baumannii. This product is recognized by the FDA as a Qualified Infectious Disease Product and has Fast Track status. A Q&A session will follow the presentations. Registration is available online.
Entasis Therapeutics Holdings (NASDAQ: ETTX) will announce its Q2 2021 financial results on August 12, 2021, before market opening. A conference call is scheduled at 8:00 AM ET to discuss the results, including a clinical and corporate update, followed by a Q&A session. Investors can join the call via phone or through a live audio webcast. Entasis specializes in developing novel antibacterial products targeting multidrug-resistant Gram-negative infections, with candidates like sulbactam-durlobactam and zoliflodacin.
Entasis Therapeutics (NASDAQ: ETTX) has announced its participation in the virtual Wedbush PacGrow Healthcare Conference on August 10-11, 2021. Management will present on August 11 at 4:40 p.m. ET, discussing the company's focus on developing novel antibacterial therapies targeting multidrug-resistant Gram-negative bacteria.
Entasis' pipeline includes treatments for infections caused by Acinetobacter baumannii, Neisseria gonorrhoeae, Enterobacteriaceae, and Pseudomonas. The presentation will be accessible via their website.
Entasis Therapeutics (NASDAQ:ETTX) has completed patient enrollment in the ATTACK Phase 3 clinical trial of SUL-DUR, aimed at treating carbapenem-resistant Acinetobacter infections. This milestone is significant as ATTACK is the first global trial specifically targeting this drug-resistant pathogen. The company anticipates releasing top-line data in early Q4 2021. With over 120 patients enrolled, primarily from ICU settings, the trial evaluates SUL-DUR's efficacy against standard treatments. This development addresses a critical unmet medical need as carbapenem-resistant Acinetobacter poses a major healthcare threat.
Entasis Therapeutics Holdings announces the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19, 2021. She brings over 20 years of experience in commercial strategy, previously at Summit Therapeutics. ATTACK Phase 3 trial results for their product SUL-DUR targeting carbapenem-resistant infections are anticipated in 2H 2021. This strategic leadership move is expected to enhance Entasis' commercialization efforts amidst the growing challenge of antimicrobial resistance.
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) presented preclinical data on ETX0462, a novel diazabicyclooctane antibiotic, at the 2021 World Microbe Forum. This first-in-class antibiotic targets multidrug-resistant Gram-negative pathogens and biothreats, potentially marking the introduction of a new antibiotic class in 35 years. ETX0462 demonstrated robust activity against clinical isolates and was well-tolerated in toxicology studies. The company anticipates advancing ETX0462 toward clinical trials in collaboration with CARB-X.
Entasis Therapeutics (NASDAQ: ETTX) announced its participation in the World Microbe Forum 2021, featuring 11 posters and one oral presentation focused on new antibacterial therapies. Key highlights include ETX0462, a novel diazabicyclooctane targeting multidrug-resistant Pseudomonas aeruginosa, and updates on SUL-DUR and ETX0282CPDP, which target Acinetobacter baumannii and Enterobacteriaceae respectively. The oral presentation for ETX0462 is scheduled for June 21, 2021. This showcases Entasis' commitment to combating antibiotic resistance through innovative solutions.
Entasis Therapeutics (NASDAQ: ETTX) reported first-quarter 2021 financial results and provided a business update. The company is on track for its Phase 3 ATTACK trial focused on multidrug-resistant Acinetobacter infections, expecting to complete enrollment soon and deliver topline data later in 2021. Notably, Entasis secured $20 million through a private placement, enhancing its cash runway into Q2 2022. The net loss for Q1 2021 was $10.7 million, a decrease from $15.3 million in Q1 2020, attributed to reduced operating expenses.
Entasis Therapeutics Holdings (Nasdaq: ETTX) announced a $7.5 million stock and warrant issuance to Innoviva (Nasdaq: INVA) on May 3, 2021. Innoviva will purchase a total of $20 million in Entasis common stock, pending stockholder approval. The initial closing involved the sale of approximately 3.7 million shares at $2.00 each. The proceeds will fund the development of antibacterial products targeting drug-resistant infections, including sulbactam-durlobactam and zoliflodacin, both in Phase 3 trials.
Entasis Therapeutics (NASDAQ: ETTX) reported a net loss of $50.5 million for FY 2020, up from $43.9 million in FY 2019, primarily due to decreased revenue. The ATTACK trial for its investigational drug, sulbactam-durlobactam, is over 75% enrolled, with topline data expected in H2 2021. The company also supports an ongoing Phase 3 trial for zoliflodacin targeting uncomplicated gonorrhea. Despite challenges from the COVID-19 pandemic, Entasis expects to complete enrollment soon and anticipates sufficient cash to fund operations through Q1 2022.
